1
|
Desai S, Behbahani-Nejad O, Dicken F, Park J, Beydoun N, Alras Z, Alkhoder A, Alvi Z, Faridizad R, Kauser T, Martini MA, Ejaz K, Liu C, Ko YA, Quyyumi AA. C-PEPTIDE CORRELATES WITH ADVERSE EVENTS IN A DIVERSE, HIGH-RISK CORONARY ARTERY DISEASE COHORT. J Am Coll Cardiol 2023. [DOI: 10.1016/s0735-1097(23)01661-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 03/07/2023]
|
2
|
Beydoun N, Niberon Y, Arnaud L, Proust J, Nomenyo K, Zeng S, Lerondel G, Bruyant A. Stabilization of Copper-Based Biochips with Alumina for Biosensing Application. Biosensors (Basel) 2022; 12:1132. [PMID: 36551099 PMCID: PMC9775342 DOI: 10.3390/bios12121132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 10/16/2022] [Revised: 11/26/2022] [Accepted: 11/28/2022] [Indexed: 06/17/2023]
Abstract
Surface plasmon resonance devices typically rely on the use of gold-coated surfaces, but the use of more abundant metals is desirable for the long-term development of plasmonic biochips. As a substitute for gold, thin copper films have been deposited on glass coverslips by thermal evaporation. As expected, these films immersed in a water solution initially exhibit an intense plasmonic resonance comparable to gold. However, without protection, an angle-resolved optical analysis shows a rapid degradation of the copper, characterized by a continuous angular shift of the plasmonic resonance curve. We show that copper films protected with a thin layer of aluminum oxide of a few nanometers can limit the oxidation rate for a sufficient time to perform some standard measurements. As the process is simple and compatible with the current biochip production technique, such an approach could pave the way for the production of alternative and more sustainable biochips.
Collapse
Affiliation(s)
- Nour Beydoun
- Light, Nanomaterials & Nanotechnologies (L2n), CNRS-ERL 7004, Université de Technologie de Troyes, 10000 Troyes, France
| | - Yann Niberon
- Light, Nanomaterials & Nanotechnologies (L2n), CNRS-ERL 7004, Université de Technologie de Troyes, 10000 Troyes, France
| | - Laurent Arnaud
- Phaselab Instrument SAS, 10325 Rosières-près-Troyes, France
| | - Julien Proust
- Light, Nanomaterials & Nanotechnologies (L2n), CNRS-ERL 7004, Université de Technologie de Troyes, 10000 Troyes, France
| | - Komla Nomenyo
- Phaselab Instrument SAS, 10325 Rosières-près-Troyes, France
| | - Shuwen Zeng
- Light, Nanomaterials & Nanotechnologies (L2n), CNRS-ERL 7004, Université de Technologie de Troyes, 10000 Troyes, France
| | - Gilles Lerondel
- Light, Nanomaterials & Nanotechnologies (L2n), CNRS-ERL 7004, Université de Technologie de Troyes, 10000 Troyes, France
| | - Aurelien Bruyant
- Light, Nanomaterials & Nanotechnologies (L2n), CNRS-ERL 7004, Université de Technologie de Troyes, 10000 Troyes, France
| |
Collapse
|
3
|
Rouphael N, Beck A, Kirby AE, Liu P, Natrajan MS, Lai L, Phadke V, Winston J, Raabe V, Collins MH, Girmay T, Alvarez A, Beydoun N, Karmali V, Altieri-Rivera J, Lindesmith LC, Anderson EJ, Wang Y, El-Khorazaty J, Petrie C, Baric RS, Baqar S, Moe CL, Mulligan MJ. Dose-Response of a Norovirus GII.2 Controlled Human Challenge Model Inoculum. J Infect Dis 2022; 226:1771-1780. [PMID: 35137154 PMCID: PMC9650503 DOI: 10.1093/infdis/jiac045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2021] [Accepted: 02/03/2022] [Indexed: 12/16/2022] Open
Abstract
BACKGROUND Genogroup II noroviruses are the most common cause of acute infectious gastroenteritis. We evaluated the use of a new GII.2 inoculum in a human challenge. METHODS Forty-four healthy adults (36 secretor-positive and 8 secretor-negative for histo-blood group antigens) were challenged with ascending doses of a new safety-tested Snow Mountain virus (SMV) GII.2 norovirus inoculum (1.2 × 104 to 1.2 × 107 genome equivalent copies [GEC]; n = 38) or placebo (n = 6). Illness was defined as diarrhea and/or vomiting postchallenge in subjects with evidence of infection (defined as GII.2 norovirus RNA detection in stool and/or anti-SMV immunoglobulin G [IgG] seroconversion). RESULTS The highest dose was associated with SMV infection in 90%, and illness in 70% of subjects with 10 of 12 secretor-positive (83%) and 4 of 8 secretor-negative (50%) becoming ill. There was no association between prechallenge anti-SMV serum IgG concentration, carbohydrate-binding blockade antibody, or salivary immunoglobulin A and infection. The median infectious dose (ID50) was 5.1 × 105 GEC. CONCLUSIONS High rates of infection and illness were observed in both secretor-positive and secretor-negative subjects in this challenge study. However, a high dose will be required to achieve the target of 75% illness to make this an efficient model for evaluating potential norovirus vaccines and therapeutics. CLINICAL TRIALS REGISTRATION NCT02473224.
Collapse
Affiliation(s)
- Nadine Rouphael
- Hope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine, School of Medicine, Emory University, Atlanta, Georgia, USA
| | - Allison Beck
- Hope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine, School of Medicine, Emory University, Atlanta, Georgia, USA
| | - Amy E Kirby
- Rollins School of Public Health, Emory University, Atlanta, Georgia, USA
| | - Pengbo Liu
- Rollins School of Public Health, Emory University, Atlanta, Georgia, USA
| | - Muktha S Natrajan
- Hope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine, School of Medicine, Emory University, Atlanta, Georgia, USA
| | - Lilin Lai
- Hope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine, School of Medicine, Emory University, Atlanta, Georgia, USA
| | - Varun Phadke
- Hope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine, School of Medicine, Emory University, Atlanta, Georgia, USA
| | - Juton Winston
- Hope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine, School of Medicine, Emory University, Atlanta, Georgia, USA
| | - Vanessa Raabe
- New York University Grossman School of Medicine and New York University Vaccine Center, New York, New York, USA
| | - Matthew H Collins
- Hope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine, School of Medicine, Emory University, Atlanta, Georgia, USA
| | - Tigisty Girmay
- Hope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine, School of Medicine, Emory University, Atlanta, Georgia, USA
| | - Alicarmen Alvarez
- Hope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine, School of Medicine, Emory University, Atlanta, Georgia, USA
| | - Nour Beydoun
- Hope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine, School of Medicine, Emory University, Atlanta, Georgia, USA
| | - Vinit Karmali
- Hope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine, School of Medicine, Emory University, Atlanta, Georgia, USA
| | - Joanne Altieri-Rivera
- Hope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine, School of Medicine, Emory University, Atlanta, Georgia, USA
| | - Lisa C Lindesmith
- Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
| | - Evan J Anderson
- Division of Infectious Diseases, Department of Pediatrics, School of Medicine, Emory University, Atlanta, Georgia, USA
| | - Yuke Wang
- Rollins School of Public Health, Emory University, Atlanta, Georgia, USA
| | | | - Carey Petrie
- The Emmes Company, LLC, Rockville, Maryland, USA
| | - Ralph S Baric
- Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
| | - Shahida Baqar
- Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
| | - Christine L Moe
- Rollins School of Public Health, Emory University, Atlanta, Georgia, USA
| | - Mark J Mulligan
- New York University Grossman School of Medicine and New York University Vaccine Center, New York, New York, USA
| |
Collapse
|
4
|
Wang G, Stapleton JT, Baker AW, Rouphael N, Creech CB, El Sahly HM, Stout JE, Jackson L, Charbek E, Leyva FJ, Tomashek KM, Tibbals M, Miller A, Frey S, Niemotka S, Wiemken TL, Beydoun N, Alaaeddine G, Turner N, Walter EB, Chamberland R, Abate G. Clinical features and treatment outcomes of pulmonary Mycobacterium avium-intracellulare complex with and without co-infections. Open Forum Infect Dis 2022; 9:ofac375. [PMID: 35959208 PMCID: PMC9361173 DOI: 10.1093/ofid/ofac375] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2022] [Accepted: 07/25/2022] [Indexed: 11/18/2022] Open
Abstract
Coinfections are more common in patients with cystic fibrosis and bronchiectasis. Infiltrates on imaging studies are seen more commonly in patients with coinfections, but coinfections did not affect treatment outcomes of pulmonary Mycobacterium avium complex.
Collapse
Affiliation(s)
- Grace Wang
- Department of Internal Medicine, Saint Louis University, St Louis, Missouri, USA
| | - Jack T Stapleton
- Department of Internal Medicine, University of Iowa, Iowa City, Iowa, USA
| | - Arthur W Baker
- Duke University School of Medicine, Durham, North Carolina, USA
| | - Nadine Rouphael
- Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | - C Buddy Creech
- Vanderbilt Vaccine Research Program, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Hana M El Sahly
- Baylor College of Medicine, Human Vaccine Institute, Houston, Texas, USA
| | - Jason E Stout
- Duke University School of Medicine, Durham, North Carolina, USA
| | - Lisa Jackson
- Kaiser Permanente Washington Health Research Institute, Seattle, Washington, USA
| | - Edward Charbek
- Department of Internal Medicine, Saint Louis University, St Louis, Missouri, USA
| | - Francisco J Leyva
- Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA
| | - Kay M Tomashek
- Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA
| | - Melinda Tibbals
- Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA
| | - Aaron Miller
- Department of Internal Medicine, Saint Louis University, St Louis, Missouri, USA
| | - Sharon Frey
- Department of Internal Medicine, Saint Louis University, St Louis, Missouri, USA
| | - Samson Niemotka
- Department of Internal Medicine, Saint Louis University, St Louis, Missouri, USA
| | - Timothy L Wiemken
- Department of Internal Medicine, Saint Louis University, St Louis, Missouri, USA
| | - Nour Beydoun
- Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Ghina Alaaeddine
- Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Nicholas Turner
- Duke University School of Medicine, Durham, North Carolina, USA
| | | | - Robin Chamberland
- Department of Pathology, Division of Clinical Pathology, Saint Louis University School of Medicine, St Louis, Missouri, USA
| | - Getahun Abate
- Correspondence: Getahun Abate, MD, PhD, Department of Internal Medicine, Saint Louis University, 1100 S Grand Blvd, Saint Louis, MO 63104, USA ()
| |
Collapse
|
5
|
Rtimi M, Beydoun N, Movsesyan A, Akil S, Kostcheev S, Gassmann X, Lajnef M, Chtourou R, Jradi S. Enhanced Photocatalytic Activity and Photoluminescence of ZnO Nano-Wires Coupled with Aluminum Nanostructures. Nanomaterials 2022; 12:nano12111941. [PMID: 35683800 PMCID: PMC9182769 DOI: 10.3390/nano12111941] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/18/2022] [Revised: 05/23/2022] [Accepted: 05/27/2022] [Indexed: 02/04/2023]
Abstract
In this study, we fabricated a hybrid plasmonic/semiconductor material by combining the chemical bath deposition of zinc oxide nanowires (ZnONWs) with the physical vapor deposition of aluminum nanostructures (AlNSs) under controlled temperature and atmosphere. The morphological and the optical properties of the ZnONWs/AlNSs hybrid material fabricated at different temperatures (250, 350, and 450 °C) and thicknesses (5, 7, and 9 nm) of Al layers were investigated. By adjusting the deposition and annealing parameters, it was possible to tune the size distribution of the AlNSs. The resonant coupling between the plasmonic AlNSs and ZnONWs leads to an enhanced photoluminescence response. The photocatalytic activity was studied through photodegradation under UV-light irradiation of methylene blue (MB) adsorbed at the surface of ZnO. The MB photodegradation experiment reveals that the ZnONWs covered with 7 nm aluminum film and annealed at 450 °C exhibit the highest degradation efficiency. The comparison between ZnONws and ZnONws/AlNSs shows a photoluminescence enhancement factor of 1.7 and an increase in the kinetics constant of photodegradation with a factor of 4.
Collapse
Affiliation(s)
- Mondher Rtimi
- Laboratory Light, Nanomaterials & Nanotechnologies (L2n—CNRS-EMR 7004), University of Technology of Troyes, 10004 Troyes, France; (M.R.); (N.B.); (A.M.); (S.K.); (X.G.)
- Faculty of Sciences of Tunis, University of Tunis El Manar, Tunis 2092, Tunisia
- Research and Technology Centre of Energy, Borj Cedria B.P N° 95, Hammam-Lif 2050, Tunisia; (M.L.); (R.C.)
| | - Nour Beydoun
- Laboratory Light, Nanomaterials & Nanotechnologies (L2n—CNRS-EMR 7004), University of Technology of Troyes, 10004 Troyes, France; (M.R.); (N.B.); (A.M.); (S.K.); (X.G.)
| | - Artur Movsesyan
- Laboratory Light, Nanomaterials & Nanotechnologies (L2n—CNRS-EMR 7004), University of Technology of Troyes, 10004 Troyes, France; (M.R.); (N.B.); (A.M.); (S.K.); (X.G.)
| | - Suzanna Akil
- LCP-A2MC Laboratory, Jean Barriol Institute, University of Lorraine, 1 Bd Arago, 57070 Metz, France;
| | - Sergei Kostcheev
- Laboratory Light, Nanomaterials & Nanotechnologies (L2n—CNRS-EMR 7004), University of Technology of Troyes, 10004 Troyes, France; (M.R.); (N.B.); (A.M.); (S.K.); (X.G.)
| | - Xavier Gassmann
- Laboratory Light, Nanomaterials & Nanotechnologies (L2n—CNRS-EMR 7004), University of Technology of Troyes, 10004 Troyes, France; (M.R.); (N.B.); (A.M.); (S.K.); (X.G.)
| | - Mohamed Lajnef
- Research and Technology Centre of Energy, Borj Cedria B.P N° 95, Hammam-Lif 2050, Tunisia; (M.L.); (R.C.)
| | - Radhouane Chtourou
- Research and Technology Centre of Energy, Borj Cedria B.P N° 95, Hammam-Lif 2050, Tunisia; (M.L.); (R.C.)
| | - Safi Jradi
- Laboratory Light, Nanomaterials & Nanotechnologies (L2n—CNRS-EMR 7004), University of Technology of Troyes, 10004 Troyes, France; (M.R.); (N.B.); (A.M.); (S.K.); (X.G.)
- Correspondence:
| |
Collapse
|
6
|
Yadalam A, Almuwaqqat Z, Desai S, Beydoun N, Alkhoder A, Alras Z, Ko YA, Lewis T, Kim JH, Shah AJ, Sperling LS, Quyyumi AA. LIVING IN SOCIALLY VULNERABLE NEIGHBORHOODS PREDICTS FUTURE CARDIOVASCULAR EVENTS IN PATIENTS WITH CORONARY ARTERY DISEASE. J Am Coll Cardiol 2022. [DOI: 10.1016/s0735-1097(22)01978-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
7
|
Moran CA, Collins LF, Beydoun N, Mehta PK, Fatade Y, Isiadinso I, Lewis TT, Weber B, Goldstein J, Ofotokun I, Quyyumi A, Choi MY, Titanji K, Lahiri CD. Cardiovascular Implications of Immune Disorders in Women. Circ Res 2022; 130:593-610. [PMID: 35175848 PMCID: PMC8869407 DOI: 10.1161/circresaha.121.319877] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Immune responses differ between men and women, with women at higher risk of developing chronic autoimmune diseases and having more robust immune responses to many viruses, including HIV and hepatitis C virus. Although immune dysregulation plays a prominent role in chronic systemic inflammation, a key driver in the development of atherosclerotic cardiovascular disease (ASCVD), standard ASCVD risk prediction scores underestimate risk in populations with immune disorders, particularly women. This review focuses on the ASCVD implications of immune dysregulation due to disorders with varying global prevalence by sex: autoimmune disorders (female predominant), HIV (male-female equivalent), and hepatitis C virus (male predominant). Factors contributing to ASCVD in women with immune disorders, including traditional risk factors, dysregulated innate and adaptive immunity, sex hormones, and treatment modalities, are discussed. Finally, the need to develop new ASCVD risk stratification tools that incorporate variables specific to populations with chronic immune disorders, particularly in women, is emphasized.
Collapse
Affiliation(s)
- Caitlin A. Moran
- Emory University School of Medicine, Department of Medicine, Division of Infectious Diseases, Atlanta, GA, USA
| | - Lauren F. Collins
- Emory University School of Medicine, Department of Medicine, Division of Infectious Diseases, Atlanta, GA, USA
| | - Nour Beydoun
- Emory University School of Medicine, Department of Medicine, Center for Heart Disease Prevention, Division of Cardiology and Emory Women’s Heart Center, Atlanta, GA, USA
| | - Puja K. Mehta
- Emory University School of Medicine, Department of Medicine, Center for Heart Disease Prevention, Division of Cardiology and Emory Women’s Heart Center, Atlanta, GA, USA
| | - Yetunde Fatade
- Emory University School of Medicine, Department of Medicine, Atlanta, GA, USA
| | - Ijeoma Isiadinso
- Emory University School of Medicine, Department of Medicine, Center for Heart Disease Prevention, Division of Cardiology and Emory Women’s Heart Center, Atlanta, GA, USA
| | - Tené T Lewis
- Emory University, Rollins School of Public Health, Department of Epidemiology, Atlanta, GA, USA
| | - Brittany Weber
- Harvard Medical School, Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USA
| | - Jill Goldstein
- Massachusetts General Hospital, Department of Psychiatry, and Harvard Medical School, Departments of Psychiatry and Medicine, Boston, MA, USA
| | - Igho Ofotokun
- Emory University School of Medicine, Department of Medicine, Division of Infectious Diseases, Atlanta, GA, USA
| | - Arshed Quyyumi
- Emory University School of Medicine, Department of Medicine, Center for Heart Disease Prevention, Division of Cardiology and Emory Women’s Heart Center, Atlanta, GA, USA
| | - May Y. Choi
- Cumming School of Medicine, University of Calgary, Calgary, AB Canada
| | - Kehmia Titanji
- Emory University, Department of Medicine, Division of Endocrinology, Metabolism, and Lipids, Atlanta, GA, USA
| | - Cecile D. Lahiri
- Emory University School of Medicine, Department of Medicine, Division of Infectious Diseases, Atlanta, GA, USA
| |
Collapse
|
8
|
Islam SJ, Beydoun N, Mehta A, Kim JH, Ko YA, Jin Q, Baltrus P, Topel ML, Liu C, Mujahid MS, Vaccarino V, Sims M, Ejaz K, Searles C, Dunbar SB, Lewis TT, Taylor HA, Pemu P, Quyyumi AA. Association of physical activity with arterial stiffness among Black adults. Vasc Med 2021; 27:13-20. [PMID: 34549642 DOI: 10.1177/1358863x211032725] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Arterial stiffness is a precursor for the development of hypertension and premature cardiovascular disease (CVD). Physical activity has been associated with lower arterial stiffness among largely White populations, but the types of activity required and whether these findings apply to Black adults remain unknown. We examined whether physical activity levels were associated with arterial stiffness among Black adults in two independent cohorts. In the Morehouse-Emory Cardiovascular (MECA) Center for Health Equity, 378 Black adults (age 52.8 ± 10.3, 39.7% male) without known CVD living in Atlanta, GA were recruited. Arterial stiffness was measured as pulse wave velocity (PWV). Total and domain-specific physical activity were assessed by self-report. Multiple linear regression models were used to investigate differences across physical activity levels after adjusting for age, sex, CVD risk factors, and socioeconomic status. Findings were validated in an independent cohort of Black adults (n = 55, age 50.4 ± 9.2, 23.6% male). After adjustment for covariates, lower arterial stiffness was associated with higher self-reported levels of sport/exercise (6.92 ± 1.13 vs 7.75 ± 1.14, p < 0.001, highest vs lowest quartile) and home/life activities (7.34 ± 1.24 vs 7.73 ± 1.07, p = 0.04, highest vs lowest quartile), but not work, active living, or the overall physical activity scores. These findings were replicated in the independent cohort where higher levels of sport/exercise remained associated with lower arterial stiffness (6.66 ± 0.57 vs 8.21 ± 0.66, p < 0.001, highest vs lowest quartile). Higher levels of sport/exercise and home/life-related physical activities (in comparison to occupational physical activity) are associated with lower arterial stiffness in Black adults.
Collapse
Affiliation(s)
- Shabatun J Islam
- Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA
| | - Nour Beydoun
- Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA
| | - Anurag Mehta
- Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA
| | - Jeong Hwan Kim
- Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA
| | - Yi-An Ko
- Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA, USA
| | - Qingchun Jin
- Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA, USA
| | - Peter Baltrus
- Department of Community Health and Preventive Medicine, Morehouse School of Medicine, Atlanta, GA, USA.,National Center for Primary Care, Morehouse School of Medicine, Atlanta, GA, USA
| | - Matthew L Topel
- Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA
| | - Chang Liu
- Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA.,Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA
| | - Mahasin S Mujahid
- Division of Epidemiology, School of Public Health, University of California, Berkeley, Berkeley, CA, USA
| | - Viola Vaccarino
- Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA.,Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA
| | - Mario Sims
- Department of Medicine, University of Mississippi Medical Center, Jackson, MS, USA
| | - Kiran Ejaz
- Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA
| | - Charles Searles
- Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA
| | - Sandra B Dunbar
- Nell Hodgson Woodruff School of Nursing, Emory University, Atlanta, GA, USA
| | - Tené T Lewis
- Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA
| | - Herman A Taylor
- Department of Medicine, Morehouse School of Medicine, Atlanta, GA, USA
| | - Priscilla Pemu
- Department of Medicine, Morehouse School of Medicine, Atlanta, GA, USA
| | - Arshed A Quyyumi
- Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA
| |
Collapse
|
9
|
Vatsa N, Almuwaqqat Z, Kim JH, Islam SJ, Tahhan AS, Mehta A, Ahmad S, Beydoun N, Ejaz K, Dhindsa D, Alkhoder A, Ko YA, Sperling L, David R, Quyyumi A. THE ASSOCIATION BETWEEN RESTLESS LEGS SYNDROME AND SOLUBLE UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR - A CONNECTION TO CARDIOVASCULAR DISEASE. J Am Coll Cardiol 2021. [DOI: 10.1016/s0735-1097(21)03166-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
10
|
Edara VV, Norwood C, Floyd K, Lai L, Davis-Gardner ME, Hudson WH, Mantus G, Nyhoff LE, Adelman MW, Fineman R, Patel S, Byram R, Gomes DN, Michael G, Abdullahi H, Beydoun N, Panganiban B, McNair N, Hellmeister K, Pitts J, Winters J, Kleinhenz J, Usher J, O'Keefe JB, Piantadosi A, Waggoner JJ, Babiker A, Stephens DS, Anderson EJ, Edupuganti S, Rouphael N, Ahmed R, Wrammert J, Suthar MS. Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant. Cell Host Microbe 2021; 29:516-521.e3. [PMID: 33798491 PMCID: PMC7980225 DOI: 10.1016/j.chom.2021.03.009] [Citation(s) in RCA: 154] [Impact Index Per Article: 51.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2021] [Revised: 03/09/2021] [Accepted: 03/16/2021] [Indexed: 02/06/2023]
Abstract
The emergence of SARS-CoV-2 variants with mutations in the spike protein is raising concerns about the efficacy of infection- or vaccine-induced antibodies. We compared antibody binding and live virus neutralization of sera from naturally infected and Moderna-vaccinated individuals against two SARS-CoV-2 variants: B.1 containing the spike mutation D614G and the emerging B.1.351 variant containing additional spike mutations and deletions. Sera from acutely infected and convalescent COVID-19 patients exhibited a 3-fold reduction in binding antibody titers to the B.1.351 variant receptor-binding domain of the spike protein and a 3.5-fold reduction in neutralizing antibody titers against SARS-CoV-2 B.1.351 variant compared to the B.1 variant. Similar results were seen with sera from Moderna-vaccinated individuals. Despite reduced antibody titers against the B.1.351 variant, sera from infected and vaccinated individuals containing polyclonal antibodies to the spike protein could still neutralize SARS-CoV-2 B.1.351, suggesting that protective humoral immunity may be retained against this variant.
Collapse
Affiliation(s)
- Venkata Viswanadh Edara
- Center for Childhood Infections and Vaccines of Children's Healthcare of Atlanta, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA; Emory Vaccine Center, Emory University, Atlanta, GA 30322, USA; Yerkes National Primate Research Center, Atlanta, GA 30329, USA
| | - Carson Norwood
- Center for Childhood Infections and Vaccines of Children's Healthcare of Atlanta, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA; Emory Vaccine Center, Emory University, Atlanta, GA 30322, USA; Department of Medicine, Emory University School of Medicine, Atlanta, GA 30329, USA
| | - Katharine Floyd
- Center for Childhood Infections and Vaccines of Children's Healthcare of Atlanta, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA; Emory Vaccine Center, Emory University, Atlanta, GA 30322, USA; Yerkes National Primate Research Center, Atlanta, GA 30329, USA
| | - Lilin Lai
- Center for Childhood Infections and Vaccines of Children's Healthcare of Atlanta, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA; Emory Vaccine Center, Emory University, Atlanta, GA 30322, USA; Yerkes National Primate Research Center, Atlanta, GA 30329, USA
| | - Meredith E Davis-Gardner
- Center for Childhood Infections and Vaccines of Children's Healthcare of Atlanta, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA; Emory Vaccine Center, Emory University, Atlanta, GA 30322, USA; Yerkes National Primate Research Center, Atlanta, GA 30329, USA
| | - William H Hudson
- Department of Microbiology and Immunology, Emory University, Atlanta, GA 30322, USA
| | - Grace Mantus
- Center for Childhood Infections and Vaccines of Children's Healthcare of Atlanta, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA; Emory Vaccine Center, Emory University, Atlanta, GA 30322, USA; Department of Medicine, Emory University School of Medicine, Atlanta, GA 30329, USA
| | - Lindsay E Nyhoff
- Center for Childhood Infections and Vaccines of Children's Healthcare of Atlanta, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA; Emory Vaccine Center, Emory University, Atlanta, GA 30322, USA; Department of Medicine, Emory University School of Medicine, Atlanta, GA 30329, USA
| | - Max W Adelman
- Department of Medicine, Emory University School of Medicine, Atlanta, GA 30329, USA
| | - Rebecca Fineman
- Department of Medicine, Emory University School of Medicine, Atlanta, GA 30329, USA
| | - Shivan Patel
- Department of Medicine, Emory University School of Medicine, Atlanta, GA 30329, USA
| | - Rebecca Byram
- Department of Medicine, Emory University School of Medicine, Atlanta, GA 30329, USA
| | - Dumingu Nipuni Gomes
- Department of Medicine, Emory University School of Medicine, Atlanta, GA 30329, USA
| | - Garett Michael
- Department of Medicine, Emory University School of Medicine, Atlanta, GA 30329, USA
| | - Hayatu Abdullahi
- Department of Medicine, Emory University School of Medicine, Atlanta, GA 30329, USA
| | - Nour Beydoun
- Department of Medicine, Emory University School of Medicine, Atlanta, GA 30329, USA
| | - Bernadine Panganiban
- Department of Medicine, Emory University School of Medicine, Atlanta, GA 30329, USA
| | - Nina McNair
- Department of Medicine, Emory University School of Medicine, Atlanta, GA 30329, USA
| | - Kieffer Hellmeister
- Department of Medicine, Emory University School of Medicine, Atlanta, GA 30329, USA
| | - Jamila Pitts
- Department of Medicine, Emory University School of Medicine, Atlanta, GA 30329, USA
| | - Joy Winters
- Department of Medicine, Emory University School of Medicine, Atlanta, GA 30329, USA
| | - Jennifer Kleinhenz
- Department of Medicine, Emory University School of Medicine, Atlanta, GA 30329, USA
| | - Jacob Usher
- Department of Medicine, Emory University School of Medicine, Atlanta, GA 30329, USA
| | - James B O'Keefe
- Department of Medicine, Emory University School of Medicine, Atlanta, GA 30329, USA
| | - Anne Piantadosi
- Department of Medicine, Emory University School of Medicine, Atlanta, GA 30329, USA; Department of Pathology and Laboratory Medicine, Emory University School of Medicine Atlanta, Georgia, USA
| | - Jesse J Waggoner
- Department of Medicine, Emory University School of Medicine, Atlanta, GA 30329, USA
| | - Ahmed Babiker
- Department of Medicine, Emory University School of Medicine, Atlanta, GA 30329, USA; Department of Pathology and Laboratory Medicine, Emory University School of Medicine Atlanta, Georgia, USA
| | - David S Stephens
- Emory Vaccine Center, Emory University, Atlanta, GA 30322, USA; Department of Medicine, Emory University School of Medicine, Atlanta, GA 30329, USA
| | - Evan J Anderson
- Center for Childhood Infections and Vaccines of Children's Healthcare of Atlanta, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA
| | - Srilatha Edupuganti
- Department of Medicine, Emory University School of Medicine, Atlanta, GA 30329, USA; Hope Clinic of Emory Vaccine Center, Emory University, Decatur, GA 30030, USA
| | - Nadine Rouphael
- Department of Medicine, Emory University School of Medicine, Atlanta, GA 30329, USA; Hope Clinic of Emory Vaccine Center, Emory University, Decatur, GA 30030, USA
| | - Rafi Ahmed
- Emory Vaccine Center, Emory University, Atlanta, GA 30322, USA; Department of Microbiology and Immunology, Emory University, Atlanta, GA 30322, USA
| | - Jens Wrammert
- Center for Childhood Infections and Vaccines of Children's Healthcare of Atlanta, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA; Emory Vaccine Center, Emory University, Atlanta, GA 30322, USA.
| | - Mehul S Suthar
- Center for Childhood Infections and Vaccines of Children's Healthcare of Atlanta, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA; Emory Vaccine Center, Emory University, Atlanta, GA 30322, USA; Department of Microbiology and Immunology, Emory University, Atlanta, GA 30322, USA; Yerkes National Primate Research Center, Atlanta, GA 30329, USA.
| |
Collapse
|
11
|
Abate G, Stapleton JT, Rouphael N, Creech B, Stout JE, El Sahly HM, Jackson L, Leyva FJ, Tomashek KM, Tibbals M, Watson N, Miller A, Charbek E, Siegner J, Sokol-Anderson M, Nayak R, Dahlberg G, Winokur P, Alaaeddine G, Beydoun N, Sokolow K, Kown NP, Phillips S, Baker AW, Turner N, Walter E, Guy E, Frey S. Variability in the Management of Adults With Pulmonary Nontuberculous Mycobacterial Disease. Clin Infect Dis 2021; 72:1127-1137. [PMID: 32198521 PMCID: PMC8028102 DOI: 10.1093/cid/ciaa252] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2019] [Accepted: 03/09/2020] [Indexed: 01/15/2023] Open
Abstract
BACKGROUND The increasing global prevalence of pulmonary nontuberculous mycobacteria (NTM) disease has called attention to challenges in NTM diagnosis and management. This study was conducted to understand management and outcomes of patients with pulmonary NTM disease at diverse centers across the United States. METHODS We conducted a 10-year (2005-2015) retrospective study at 7 Vaccine and Treatment Evaluation Units to evaluate pulmonary NTM treatment outcomes in human immunodeficiency virus-negative adults. Demographic and clinical information was abstracted through medical record review. Microbiologic and clinical cure were evaluated using previously defined criteria. RESULTS Of 297 patients diagnosed with pulmonary NTM, the most frequent NTM species were Mycobacterium avium-intracellulare complex (83.2%), M. kansasii (7.7%), and M. abscessus (3.4%). Two hundred forty-five (82.5%) patients received treatment, while 45 (15.2%) were followed without treatment. Eighty-six patients had available drug susceptibility results; of these, >40% exhibited resistance to rifampin, ethambutol, or amikacin. Of the 138 patients with adequate outcome data, 78 (56.5%) experienced clinical and/or microbiologic cure. Adherence to the American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) treatment guidelines was significantly more common in patients who were cured (odds ratio, 4.5, 95% confidence interval, 2.0-10.4; P < .001). Overall mortality was 15.7%. CONCLUSIONS Despite ATS/IDSA Guidelines, management of pulmonary NTM disease was heterogeneous and cure rates were relatively low. Further work is required to understand which patients are suitable for monitoring without treatment and the impact of antimicrobial therapy on pulmonary NTM morbidity and mortality.
Collapse
Affiliation(s)
- Getahun Abate
- Department of Internal Medicine, Saint Louis University, St Louis, Missouri, USA
| | - Jack T Stapleton
- Department of Internal Medicine, University of Iowa, Iowa City, Iowa, USA
| | - Nadine Rouphael
- Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Buddy Creech
- Division of Infectious Diseases, Vanderbilt University, Nashville, Tennessee, USA
| | - Jason E Stout
- Duke University School of Medicine, Durham, North Carolina, USA
| | | | - Lisa Jackson
- Kaiser Permanente Washington Health Research Institute, Seattle, Washington, USA
| | - Francisco J Leyva
- Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA
| | - Kay M Tomashek
- Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA
| | - Melinda Tibbals
- Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA
| | - Nora Watson
- The Emmes Corporation, Rockville, Maryland, USA
| | - Aaron Miller
- Department of Internal Medicine, Saint Louis University, St Louis, Missouri, USA
| | - Edward Charbek
- Department of Internal Medicine, Saint Louis University, St Louis, Missouri, USA
| | - Joan Siegner
- Department of Internal Medicine, Saint Louis University, St Louis, Missouri, USA
| | | | - Ravi Nayak
- Department of Internal Medicine, Saint Louis University, St Louis, Missouri, USA
| | - Greta Dahlberg
- Department of Internal Medicine, University of Iowa, Iowa City, Iowa, USA
| | - Pat Winokur
- Department of Internal Medicine, University of Iowa, Iowa City, Iowa, USA
| | - Ghina Alaaeddine
- Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Nour Beydoun
- Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Katherine Sokolow
- Division of Infectious Diseases, Vanderbilt University, Nashville, Tennessee, USA
| | - Naomi Prashad Kown
- Division of Infectious Diseases, Vanderbilt University, Nashville, Tennessee, USA
| | - Shanda Phillips
- Division of Infectious Diseases, Vanderbilt University, Nashville, Tennessee, USA
| | - Arthur W Baker
- Duke University School of Medicine, Durham, North Carolina, USA
| | - Nicholas Turner
- Duke University School of Medicine, Durham, North Carolina, USA
| | - Emmanuel Walter
- Duke University School of Medicine, Durham, North Carolina, USA
| | | | - Sharon Frey
- Department of Internal Medicine, Saint Louis University, St Louis, Missouri, USA
| |
Collapse
|
12
|
Edara VV, Norwood C, Floyd K, Lai L, Davis-Gardner ME, Hudson WH, Mantus G, Nyhoff LE, Adelman MW, Fineman R, Patel S, Byram R, Gomes DN, Michael G, Abdullahi H, Beydoun N, Panganiban B, McNair N, Hellmeister K, Pitts J, Winters J, Kleinhenz J, Usher J, O'Keefe JB, Piantadosi A, Waggoner JJ, Babiker A, Stephens DS, Anderson EJ, Edupuganti S, Rouphael N, Ahmed R, Wrammert J, Suthar MS. Reduced binding and neutralization of infection- and vaccine-induced antibodies to the B.1.351 (South African) SARS-CoV-2 variant. bioRxiv 2021. [PMID: 33655254 DOI: 10.1101/2021.02.20.432046] [Citation(s) in RCA: 23] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
The emergence of SARS-CoV-2 variants with mutations in the spike protein is raising concerns about the efficacy of infection- or vaccine-induced antibodies to neutralize these variants. We compared antibody binding and live virus neutralization of sera from naturally infected and spike mRNA vaccinated individuals against a circulating SARS-CoV-2 B.1 variant and the emerging B.1.351 variant. In acutely-infected (5-19 days post-symptom onset), convalescent COVID-19 individuals (through 8 months post-symptom onset) and mRNA-1273 vaccinated individuals (day 14 post-second dose), we observed an average 4.3-fold reduction in antibody titers to the B.1.351-derived receptor binding domain of the spike protein and an average 3.5-fold reduction in neutralizing antibody titers to the SARS-CoV-2 B.1.351 variant as compared to the B.1 variant (spike D614G). However, most acute and convalescent sera from infected and all vaccinated individuals neutralize the SARS-CoV-2 B.1.351 variant, suggesting that protective immunity is retained against COVID-19.
Collapse
|
13
|
Beydoun N, Tandon S, Krengel S, Johnson E, Palacio Bedoya F, Moore M, Refai D, Rouphael N. A Retrospective Chart Review on the Role of Suppressive Therapy in the Management of Spinal Infections Involving Hardware. Open Forum Infect Dis 2020; 7:ofaa253. [PMID: 32715019 PMCID: PMC7372706 DOI: 10.1093/ofid/ofaa253] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2020] [Accepted: 06/19/2020] [Indexed: 11/22/2022] Open
Abstract
Background One percent to 8% of patients undergoing spinal instrumentation surgeries develop infections. There is no consensus on the medical and surgical management of these infections. Methods We conducted a retrospective chart review based on International Classification of Diseases, Ninth Revision, and Common Procedural Terminology codes relevant to spinal infections with hardware within Emory Healthcare over a 10-year period. Extracted data included patient demographics, clinical presentation, laboratory and microbiologic results, and surgical and medical management including choice and duration of suppressive therapy. Multivariable logistic regression was used to assess the association of length of use of suppressive antibiotics with treatment success and to identify predictors of use of suppressive antibiotics. Results Of 869 records, 124 met inclusion criteria. Fifty patients (40.3%) had an infection that occurred after hardware placement, mostly within 3 months postsurgery, while the remainder had vertebral osteomyelitis that required hardware placement. After initial intravenous antibiotic treatment for ≥4 weeks, 72 patients (64.5%) were given suppressive antibiotics. The overall treatment success rate was 78.2%. In spinal infections involving hardware with gram-negative rods, patients were less likely to receive suppressive antibiotics, less likely to have hardware removed, and less likely to have treatment success compared with patients with infections with Staphylococcus species. Conclusions Management of spinal infections involving hardware should be tailored to the timing of onset of infection and causative organism. Further studies are needed to determine best management practices, particularly for gram-negative rod infections where the role of further suppressive antibiotics and hardware removal may be warranted.
Collapse
Affiliation(s)
- Nour Beydoun
- Department of Internal Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.,The Hope Clinic, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Sonia Tandon
- The Hope Clinic, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Sonia Krengel
- The Hope Clinic, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Eric Johnson
- The Hope Clinic, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Federico Palacio Bedoya
- Division of Infectious Diseases, Department of Internal Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Michael Moore
- Department of Neurosurgery, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Daniel Refai
- Department of Neurosurgery, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Nadine Rouphael
- The Hope Clinic, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia, USA.,Division of Infectious Diseases, Department of Internal Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| |
Collapse
|
14
|
Shahine I, Jradi S, Beydoun N, Gaumet J, Akil S. Plasmon‐Enhanced Photoluminescence and Photocatalysis Reactions in Metal‐Semiconductor Nanomaterials: UV‐Generated Hot Electron in Gold‐Zinc Oxide. CHEMPHOTOCHEM 2019. [DOI: 10.1002/cptc.201900252] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Affiliation(s)
- Issraa Shahine
- LCP−A2MC, Institut Jean BarriolUniversité de Lorraine 1 Boulevard Arago 57070 Metz France
| | - Safi Jradi
- L2n, Lumière, Nanomatériaux, Nanotechnologies ICD, CNRSUniversité de Technologie de Troyes 12 Rue Marie-Curie 10004 Troyes France
| | - Nour Beydoun
- L2n, Lumière, Nanomatériaux, Nanotechnologies ICD, CNRSUniversité de Technologie de Troyes 12 Rue Marie-Curie 10004 Troyes France
| | - Jean‐Jacques Gaumet
- LCP−A2MC, Institut Jean BarriolUniversité de Lorraine 1 Boulevard Arago 57070 Metz France
| | - Suzanna Akil
- LCP−A2MC, Institut Jean BarriolUniversité de Lorraine 1 Boulevard Arago 57070 Metz France
| |
Collapse
|
15
|
Tabaja H, Sharara SL, Abi Aad Y, Beydoun N, Tabbal S, Makki A, Mahfouz R, Kanj SS. Varicella zoster virus infection of the central nervous system in a tertiary care center in Lebanon. Med Mal Infect 2019; 50:280-287. [PMID: 31526545 DOI: 10.1016/j.medmal.2019.08.005] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2018] [Revised: 08/20/2018] [Accepted: 08/27/2019] [Indexed: 11/28/2022]
Abstract
OBJECTIVE To describe the clinical manifestations and treatment outcomes of patients with VZV meningitis and encephalitis consulting at two medical centers in Lebanon. METHODS Retrospective study of patients with VZV meningitis and/or encephalitis confirmed by positive cerebrospinal fluid (CSF) VZV PCR. RESULTS Twenty patients were identified (13 males). The average age was 49.7±22.2 years. The most common complaint was headache (n=17/20). Common comorbidities included hypertension (n=7/20) and diabetes mellitus (n=5/20). Immunosuppression was reported in two patients. Vesicles were only observed in eight patients. Altered mental status, focal neurological deficits, and fever were documented in six, two, and four patients respectively. All patients had CSF leukocytosis with lymphocytic predominance, normal CSF/serum glucose ratio, and high CSF protein. Eighteen patients had brain CT scans showing no relevant findings. Two of 12 patients with brain MRI had focal abnormalities. Unilateral temporal slow waves were observed in three of four patients who underwent electroencephalograms. Four patients had encephalitis and 16 had meningitis. Eighteen patients received an antiviral therapy. Treatment either included intravenous acyclovir or oral valacyclovir. The encephalitis and meningitis groups had comparable mean duration of treatment (13.5±6.6 vs. 12.2±5.4, respectively). All admitted patients showed clinical cure with no reported neurological sequelae. CONCLUSION VZV infection should be suspected in any patient with signs and symptoms of viral meningitis or encephalitis, irrespective of age, immune status, presence or absence of vesicles, fever, or neck stiffness.
Collapse
Affiliation(s)
- H Tabaja
- Infectious Diseases Unit, Department of Internal Medicine, American University of Beirut Medical Center, PO Box 11-0236, Riad El Solh 1107 2020, Beirut, Lebanon
| | - S L Sharara
- The School of Medicine, American University of Beirut Medical Center, Beirut, Lebanon
| | - Y Abi Aad
- Infectious Diseases Unit, Department of Internal Medicine, American University of Beirut Medical Center, PO Box 11-0236, Riad El Solh 1107 2020, Beirut, Lebanon; The School of Medicine, American University of Beirut Medical Center, Beirut, Lebanon
| | - N Beydoun
- The School of Medicine, American University of Beirut Medical Center, Beirut, Lebanon
| | - S Tabbal
- The division of Neurology, American University of Beirut Medical Center, Beirut, Lebanon
| | - A Makki
- The division of Neurology, American University of Beirut Medical Center, Beirut, Lebanon
| | - R Mahfouz
- The division of Diagnostic Molecular Pathology, Department of Pathology and Laboratory Medicine, American University of Beirut Medical Center, Beirut, Lebanon
| | - S S Kanj
- Infectious Diseases Unit, Department of Internal Medicine, American University of Beirut Medical Center, PO Box 11-0236, Riad El Solh 1107 2020, Beirut, Lebanon.
| |
Collapse
|
16
|
Mohan S, Shafiq J, Beydoun N, Nasser E, Nguyen A, Vinod S. P3.14-003 Patterns of Follow-Up Care After Curative Radiotherapy for Stage I-III Non-Small Cell Lung Cancer. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1776] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
17
|
Turfe Z, Kasti MM, Beydoun N, Hamdan AL. Phonatory Symptoms and Acoustic Findings in Patients with Asthma: A Cross-Sectional Controlled Study. Otolaryngol Head Neck Surg 2014. [DOI: 10.1177/0194599814541629a172] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Objectives: Investigate the prevalence of phonatory symptoms, perceptual, acoustic, and aerodynamic findings in patients with asthma compared to a control group. Methods: A total of 50 subjects, 31 asthmatic and 19 control subjects matched according to age and sex, were enrolled in this study. All subjects were asked about the presence or absence of cough, dyspnea, respiratory failure, dysphonia, degree of vocal fatigue, and phonatory effort. Perceptual evaluation, acoustic analysis, and aerodynamic measurements were also performed. Patient self-assessment using the Voice Handicap Index 10 was reported. Results: The mean age of patients was 43.5 years with a female to male ratio of 2:1. There was a statistically significant difference in the prevalence of dysphonia between the 2 groups (32.3% vs 5.3%, P = .025) with a significant difference in the mean score of respiratory effort and vocal fatigue ( P = .019, .041, respectively). The overall grade of dysphonia was significantly higher in asthmatics compared to controls ( P = .002). Patients with asthma also had significantly higher degree of asthenia and straining with borderline significant difference with respect to roughness. There was no significant difference in the means of any of the acoustic parameters between patients and controls except for jitter. There was also no significant difference in the maximum phonation time between the 2 groups. Conclusions: Phonatory symptoms are significantly more prevalent in patients with asthma compared to controls.
Collapse
|